Asthma

Atrial Fibrillation

Autoimmune Diseases

Biologics

Biosimilars

Blood Cancer

Breast Cancer

COVID-19

Cardiovascular Diseases

Depression

Dermatology

Diabetes

Digital Health

Drug Coverage

Duchenne Muscular Dystrophy

Eyecare

Friedreich Ataxia

Gene Therapy

Graft Versus Host Disease

Heart Failure

Hemophilia

Hypertrophic Cardiomyopathy (HCM)

Leukemia and Lymphoma

Liver Disease

Lung Cancer

Mental Health

Multiple Sclerosis

NSCLC

Neonatal Care

Nephrology

Obstetrics-Gynecology & Women's Health

Oncology

Opioids

PTSD

Pain

Pediatrics

Plaque Psoriasis

Population Health

Post-Acute Care

Prescription Digital Therapeutics

Pulmonary Arterial Hypertension

Reproductive Health

Respiratory Conditions

Safety & Recalls

Schizophrenia

Skin Cancer

Sleep Disorders

Solid Tumors

Spinal Muscular Atrophy

Substance Use Disorder

The Improving Patient Access Podcast

Type I Diabetes

Type II Inflammation

Ulcerative Colitis

Urology

Urothelial Carcinoma

Vaccines

Women's Health

News

Media

Between the Lines

Expert Interviews

K-Cast

Medical World News

Podcasts

Population Health Perspectives

Conferences

Partners

Publications

All Publications

MHE Publication

Formulary Watch Supplements

Formulary Watch Spotlights

Supplements And Featured Publications

Events

Virtual Events

CME/CE

Resources

Emerging Leaders

Interactive Tools

PBM Leaders

PBM Directory

Subscribe

Articles

Proposed Medicaid changes could lead to 1,500 excess deaths and $135 billion in economic losses annually, impacting health care and rural communities.

Proposed Medicaid Changes Could Lead to Thousands of Preventable Deaths and Billions in Economic Losses

The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).

FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy

In this interview, Sarah Morris, chief product officer of Audere, explains why they chose to focus on women and young girls and how they have tailored their program to reach them. 

Meet Aimee, The Artificial Intelligence Ally Taking On South Africa’s HIV Crisis 

Employers increasingly shift health benefit costs to workers in 2026, while prioritizing mental health and innovative affordability strategies.

More Employers Plan to Shift Health Costs to Workers in 2026 as Benefits Grow More Expensive

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Managed Healthcare Executive - Payer and Population Health Insights

Facebook

LinkedIn

Resource Centers

Eye Care

Spotlight

PBMI Innovators

IAS 2025

AMCP Annual

K-Cast: Optimizing Narcolepsy Care

Business

Business Strategy

Chronic Disease

Consumers

Drug Costs

Drug Pipeline

Formulary

Health Management

Health/Disease Strategy

Hospitals & Providers

Industry Analysis

Pharmacy

Politics and Policy

Practice Management

Reimbursement

Technology

1rem

Jeffrey Casberg, M.S., of IPD Analytics and Luke Greenwalt, MBA, of IQVIA, both members of the 

editorial advisory board, will provide a midyear assessment of the pharmacy market and the policy and politics affecting it. Topics to be discussed include the possibility of tariffs, the most-favored nation drug pricing executive order, aspect of the reconciliation bill that could affect the pharmaceutical and pharmacy benefit management industries, pressure on the gross-to-net “bubble,” implementation of the Inflation Reduction Act price negotiations, GLP-1s and notable FDA approvals in the second half of 2025. Note that this a menu and some topics may be added or subtracted depending on time and news up to airtime on June 12. Peter Wehrwein, managing editor of 

The 2025 Pharma Trajectory

In a panel moderated by Peter Wehrwein, managing editor of 

 three Washington, D.C., healthcare lobbyists with extensive D.C. experience discussed healthcare politics and policy dynamics under the Trump administration. Ryann Hill, M.P.H.; Patrick Cooney and Lindsay Greenleaf, J.D., MBA, said healthcare remains a top issue despite all the attention on immigration, tariffs and universities. Key issues include staffing cuts at HHS, with potential effects on the operations of the FDA and the Centers for Disease Control and Prevention. They also discussed the massive reconciliation bill and Medicaid changes, including work requirements and provider tax freezes, Medicare Advantage plan rate hikes and audits, and the May 12 drug pricing executive order and the implications of most-favored nation pricing.

The New Healthcare Reality Under the Trump Administration

Three Washington, D.C., healthcare policy experts and the former chief of staff of HHS dive into the healthcare politics and policies of the new administration: RFK Jr.’s confirmation hearings; the future of IRA drug price negotiations and PBM reform; Medicare Advantage under the new administration; DOGE cuts at HHS; and ant-DEI and the social determinants of health.

What ‘Going Wild’ on Healthcare Could Mean: The Early Days of Trump Healthcare

This webinar, “Your Guide to 2025: Pharma, Formularies, the Pipeline and More” featured Luke Greenwalt, MBA,vice president and lead of the Market Access Center of Excellence at IQVIA, an Jeff Casberg, RPh, M.S., senior vice president, clinical pharmacy at IPD Analytics. Greenwalt and Casberg, both of whom are on the

editorial advisory board, discussed the market trends for GLP-1s and biosimilars; the ’25 drug pipeline; and the prospects for PBM legislation.

Your Guide to 2025: Pharma, Formularies, the Pipeline and More

This webinar on "What the Trump Presidency Will Mean for U.S. Healthcare and Managed Care" includes panelists Lindsay Greenleaf, J.D., MBA; Ryann Hill, M.P.H. and Patrick Cooney, discussing possible changes to healthcare policies and programs under the Trump administration, including the future of the Inflation Reduction and Affordable Care Acts, PBM reform and Medicare Advantage.

Ryann Hill, M.P.H., Indigo Hill Strategies; Patrick Cooney, The Federal Group; and Lindsay Bealor Greenleaf, J.D., MBA, ADVI Health. With special guest, Sean McCluskie, J.D., Ph.D., former HHS chief of staff.

What the Trump Presidency Will Mean for U.S. Healthcare and Managed Care

Explore how responsible AI technologies, exemplified by ClinicalKey AI, are helping to reshape clinical decision support to meet the evolving needs of pharmacists in ambulatory and retail settings.

Empowering Pharmacists with Responsible AI – A Patient Care Journey from a Pharmacist Perspective

Virtual Events

Empowering Pharmacists with Responsible AI – A Patient Care Journey from a Pharmacist Perspective

Date: